Phenotypes associated with this allele

• Allele Symbol: Slc1a2^tm1.1Pros
• Allele Name: targeted mutation 1.1, Paul A Rosenberg
• Allele ID: MGI:5752263
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Slc1a2^tm1.1Pros/Slc1a2^tm1.1Pros Tg(GFAP-cre/ERT2)13Kdmc/0	involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6	MGI:5771812
cn2	Slc1a2^tm1.1Pros/Slc1a2^tm1.1Pros Tg(Syn1-cre)671Jxm/0	involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6	MGI:5771813

Genotype
MGI:5771812

cn1

• Allelic Composition: Slc1a2^tm1.1Pros/Slc1a2^tm1.1Pros; Tg(GFAP-cre/ERT2)13Kdmc/0
• Genetic Background: involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:221590 )

• following postnatal tamoxifen treatment (P5-P9), mice die significantly earlier than control mice, with a median survival at 23 weeks of age

growth/size/body

slow postnatal weight gain ( J:221590 )

• tamoxifen-treated mice gain significantly less weight than controls from 10 weeks of age

behavior/neurological

behavior/neurological phenotype ( J:221590 )

N • at 28-67 weeks of age, tamoxifen-treated mice show no significant differences in total SHIRPA scores relative to control mice

seizures ( J:221590 )

• tamoxifen-treated mice show more electroencephalographic seizure events than controls

• however, no spontaneous clinical seizures are observed

nervous system

nervous system phenotype ( J:221590 )

N • at 14-19 weeks of age, tamoxifen-treated mice show only a minor, insignificant decrease in the uptake of L-[3H]glutamate (~15%) and D-[3H]aspartate (~13%) into crude forebrain synaptosomes relative to controls

seizures ( J:221590 )

• tamoxifen-treated mice show more electroencephalographic seizure events than controls

• however, no spontaneous clinical seizures are observed

abnormal brain wave pattern ( J:221590 )

• tamoxifen-treated mice show a significantly higher number of automatically detected spike-trains (electroencephalographic seizures) per 20 min of scalp EEG recording relative to controls (18.7 +/- 7.2 vs 1.9 +/- 0.5)

Genotype
MGI:5771813

cn2

• Allelic Composition: Slc1a2^tm1.1Pros/Slc1a2^tm1.1Pros; Tg(Syn1-cre)671Jxm/0
• Genetic Background: involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6

nervous system

abnormal synaptic physiology ( J:221590 )

• at 14-19 weeks of age, the synaptosomal glutamate uptake capacity (Vmax) is reduced by ~40% relative to wild-type controls

• uptake of D-[3H]aspartate into crude forebrain synaptosomes is reduced by ~49% relative to controls

• however, both the GLT-1 protein and glutamate uptake activity that could be solubilized and reconstituted in liposomes are unaffected

mortality/aging

mortality/aging ( J:221590 )

N • mice exhibit normal survival up to 70 weeks of age

growth/size/body

growth/size/body region phenotype ( J:221590 )

N • mice exhibit normal weight gain up to 24 weeks of age

behavior/neurological

behavior/neurological phenotype ( J:221590 )

N • at 12-52 weeks of age, mice show no significant differences in total SHIRPA scores relative to control mice

N • no spontaneous clinical seizures are observed

N • no electrographic seizures are detected by scalp or tethered EEG recordings